Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

ClinicalTrials.gov ID: NCT00411528

Public ClinicalTrials.gov record NCT00411528. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Multicenter Phase II Trial of Patupilone (EPO906) Plus Prednisone Versus Docetaxel Plus Prednisone in Patients With Metastatic Hormone Refractory Prostate Cancer

Study identification

NCT ID
NCT00411528
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
185 participants

Conditions and interventions

Interventions

  • Patupilone Drug
  • prednisone Drug
  • docetaxel Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2006
Primary completion
Aug 31, 2012
Completion
Aug 31, 2012
Last update posted
Dec 16, 2020

2006 – 2012

United States locations

U.S. sites
11
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
University of California San Diego Dept of Moores Cancer Center La Jolla California 92093-0658
University of Colorado Dept. of Univ. of Colorado Aurora Colorado 80045
Norwalk Hospital Norwalk Connecticut 06856
Georgetown University/Lombardi Cancer Center Dept.of Lombardi Cancer Center Washington D.C. District of Columbia 20007-2197
MD Anderson Cancer Center - Orlando CEPO906A2229 Orlando Florida 32806
H. Lee Moffitt Cancer Center/University of South Florida Department of Genitourology Tampa Florida 33612
Palm Beach Cancer Institute West Palm Beach Florida 33401
NorthWest Georgia Oncology Centers Marietta Center Marietta Georgia 30060
University Chicago Hospital StudyCoordinator:CEPO906A2229 Chicago Illinois 60637
Queens Cancer Center of Queens Hospital Jamaica New York 11432
Oregon Health & Science University StudyCoordinator:CEPO906A2229 Portland Oregon 97239

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00411528, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2020 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00411528 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →